Birch bark extract as therapy for chronic hepatitis C--a pilot study.

Area of Science:

• Hepatology
• Natural Product Chemistry
• Virology

Background:

• Chronic hepatitis C (CHC) poses a significant global health burden.
• Limited treatment options and side effects necessitate novel therapeutic approaches.
• Natural compounds are being explored for their potential hepatoprotective properties.

Purpose of the Study:

• To evaluate the efficacy of standardized birch bark extract (BBE) in patients with chronic hepatitis C.
• To assess the impact of BBE on liver enzymes, viral load, and patient-reported symptoms.
• To determine the safety and tolerability of BBE in CHC patients.

Main Methods:

• A 12-week open-label study involving 42 CHC patients treated with 160 mg/day of standardized BBE.
• Analysis of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and quantitative HCV RNA levels.
• Assessment of subjective CHC symptoms (fatigue, abdominal discomfort, depression, dyspepsia) and safety parameters.

Main Results:

• Significant reductions in mean ALT levels (54.0% normalization, p=0.046) and HCV RNA (43.2% reduction, p=0.016) were observed.
• Patient-reported fatigue decreased 6-fold (p=0.028), abdominal discomfort 3-fold (p=0.05), and dyspepsia was no longer reported (p=0.042).
• BBE was confirmed to contain 75% betulin and 3.5% betulinic acid via HPLC.

Conclusions:

• Standardized birch bark extract demonstrated promising hepatoprotective effects in CHC patients.
• BBE treatment led to significant improvements in biochemical markers and symptom relief.
• Further controlled clinical trials are warranted to confirm these findings and establish clinical relevance.